Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women

International Journal of Cardiology

Volumn 113, Issue 1, 2006, Pages 66-75

  Ushiroyama, Takahisa ^a   Nosaka, Sakura ^a   Ueki, Minoru ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Atorvastatin; Hyperlipidemia; Lipid profile; Perimenopause; Pleiotropic effects; Sex steroid production

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PLEIOTROPY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; BLOOD COAGULATION; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; FIBRINOLYSIS; GONADAL STEROID HORMONES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPIDS; LIPOPROTEINS; MALONDIALDEHYDE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; PYRROLES; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 33750427877     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.11.001     Document Type: Article

References (46)

1. Bengsston C., and Lindquist O. Menopausal effects on risk factors for ischaemic heart disease. Maturitas 1 (1979) 165-170
2. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and the risk of cardiovascular disease. The Framingham study. Ann Intern Med 85 (1976) 447-452
3. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and risk of myocardial infarction. Am J Obstet Gynecol.
4. Ushiroyama T., Okamoto Y., and Sugimoto O. Plasma lipid and lipoprotein levels in perimenopausal women. Clinical research for 1198 Japanese women. Acta Obstet Gynecol Scand 72 (1993) 428-433
5. Walsh J.M.E., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
6. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 285 (2001) 1711-1718
7. Nissen S., Tuzcu E.M., Schoenhagen P., et al. Effects of intensive compared with moderate lipid-lowering therapy in progression of coronary atherosclerosis. JAMA 291 (2004) 1071-1080
8. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scantinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
9. Ridler P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
10. Ridker P.M., Hennekens C.H., and Buring J.E. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
11. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
12. Allein C.C., Poon L.S., Chan C.S.G., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
13. Bucolo G., and David H. Quantitative determination of serum triglycerides by the use of enzyme. Clin Chem 19 (1973) 476-482
14. Talameh Y., Wei R., and Naito H. Measurements of total HDL, HDL2, HDL3 by dextran sulfate-MgCl2 precipitation technique in human serum. Clin Chim Acta 158 (1986) 33-39
15. Friedewald W.T., Levy R.I., and Frederikson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
16. Ushiroyama T., Ikeda A., Higashio S., and Ueki M. Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis 11 (2000) 709-714
17. Ushiroyama T., Yoshikawa M., and Sugimoto O. Hypergonadotropinemia with estradiol secretion in peri- and postmenopausal period. Acta Obstet Gynecol Scand 68 (1989) 139-143
18. Korenman S.G., Stevens R.H., Carpenter L.A., Robb M., Niswender G.D., and Sherman B.M. Estradiol radioimmunoassay without chromatography: procedure, validation and normal values. J Clin Endocrinol Metab 38 (1974) 718-720
19. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attack?. Ann Intern Med 130 (1999) 933-937
20. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., and Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95 (1995) 2611-2619
21. Haire W.D., Goldsmith J.C., and Raumussen J. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. Am J Hematol 31 (1989) 36-40
22. Thompson M. Blood coagulation and haemostasis. A practical guide. 3rd edn. (1985), Churchill Livingstone, New York
23. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 suppl III (2004) III-39-III-43
24. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
25. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
26. Sasaki S., Kuwahara N., Kunitomo K., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89 (2002) 386-389
27. Packard C., Caslake M., and Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74 Suppl. 1 (2000) S17-S22
28. Sakabe K., Fukuda N., Wakayama K., Nada T., Shinohara H., and Tamura Y. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. Int J Cardiol 94 (2004) 111-117
29. Lavy A., Brook G.J., Dankner G., Amotz A.B., and Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 40 (1991) 794-799
30. Tamura A., Watanabe T., and Nasu M. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J 67 (2003) 816-820
31. Hussein O., Schlezinger S., Rosenblat M., Keidar S., and Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128 (1997) 11-18
32. Cohn J.S., Marcoux C., and Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19 (1999) 2474-2486
33. Fukushima H., Kugiyama K., Sugiyama S., et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 88 (2001) 1370-1373
34. Stein D.T., Devaraj S., Balis D., Adams-Huet B., and Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 (2001) 2026-2031
35. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein I.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 357 (2001) 577-581
36. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 18 (2000) 207-213
37. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288 (2002) 2998-3007
38. Hashimoto H., Kitagawa, Hougaku H., et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 104 (2001) 63-67
39. Ridler P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infraction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) investigators. Circulation 98 (1998) 839-844
40. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, European Concerned Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 (1995) 635-641
41. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., and Wojta J. HMG-CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135 (2002) 284-292
42. Demir M., Acarturk E., Saamaz I., Cayli M., and Kikinc Y. Effects of atorvastatin on lipid profile and coagulation parameters. Curr Ther Res Clin Exp 62 (2001) 691-698
43. Sakabe K., Fukuda N., Wakayama K., Nada T., Shinohara H., and Tamura Y. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circ J 67 (2003) 866-877
44. Hernandez-Perera O., Perez-Sala D., and Navarro-Antolin J. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endotherial cells. J Clin Invest 101 (1998) 2711-2719
45. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33 (1999) 234-241
46. Ushiroyama T., Ikeda A., and Ueki M. Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels. Maturitas 37 (2001) 201-208